[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Pereira CM, Lopes AP, Meneghini AJ, Silva GB, Monteiro MC, Botelho Tde L: Burkitt's lymphoma in a young Brazilian boy. Malays J Pathol; 2010 Jun;32(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in a young Brazilian boy.
  • Burkitt's lymphoma is not an uncommon malignancy in the paediatric population.
  • It is a high-grade non-Hodgkin B-cell lymphoma which may present as endemic, sporadic and human immunodeficiency-associated subtypes.
  • The African, or endemic, variant usually involves the maxilla and other facial bones while head and neck manifestations in sporadic Burkitt's lymphoma are rare.
  • We described a case of oral Burkitt's lymphoma involving the right jaw in a 4-year-old boy.
  • The patient presented with a rapidly-enlarging swelling of one month duration, toothache-like pain and radiographical appearance of 'floating teeth' in the right mandible.
  • Tumour remission was achieved with six cycles of chemotherapy with the CHOP regime.
  • [MeSH-major] Burkitt Lymphoma / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Antigens, CD20 / biosynthesis. Antigens, CD3 / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Brazil. Child, Preschool. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Neprilysin / biosynthesis. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614728.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Pagano L, Caira M, Valentini CG, Fianchi L: Clinical aspects and therapy of sporadic burkitt lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects and therapy of sporadic burkitt lymphoma.
  • Burkitt's lymphoma is a highly aggressive mature B-cell neoplasm consisting of endemic, sporadic, and immunodeficiency-associated variants, sharing many morphologic and immunophenotypic features.
  • Brief-duration, high-intensity chemotherapy regimens including aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease in the sporadic form, with very high complete remission rate and overall survival in adults.
  • Although Burkitt's lymphoma is extremely chemosensitive, biologically targeted therapies should be developed, because current treatment options are suboptimal for patients with poor prognostic features or with relapsed disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1130-4 [1515634.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Oligonucleotides. 2005 Summer;15(2):85-93 [15989423.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):941-6 [1709685.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):177-81 [18816698.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(12):1311-3 [10871739.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):889-92 [12153181.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):815-20 [15352985.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):31-40 [16865529.001]
  • [Cites] Cancer Gene Ther. 2007 Feb;14(2):220-6 [17053816.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):240-8 [8558204.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):931-6 [8487057.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1351-4 [11223978.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):615-22 [2313330.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):847-58 [3711961.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1695-704 [6697306.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • (PMID = 21416007.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033171
  •  go-up   go-down


3. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS, UK National Cancer Research Institute Lymphoma Clinical Studies Group, Australasian Leukaemia and Lymphoma Group: A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood; 2008 Sep 15;112(6):2248-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
  • This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified (dm) CODOX-M/IVAC in patients diagnosed using these criteria.
  • The study was open to patients with an aggressive B-cell lymphoma with an MKI67 fraction approaching 100%.
  • BL was characterized by the presence of a cMYC rearrangement as a sole cytogenetic abnormality occurring in patients with a germinal center phenotype with absence of BCL-2 expression and abnormal TP53 expression.
  • A total of 128 patients were eligible for the study, of whom 58 were considered to have BL and 70 to have diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytogenetic Analysis. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Immunophenotyping. Methotrexate / administration & dosage. Middle Aged. Treatment Outcome. Vincristine / administration & dosage

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1136-43 [11830458.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2133-9 [12796378.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Br J Haematol. 1999 May;105(2):437-40 [10233417.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):568-74 [17006262.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6930-9 [17082608.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2345-52 [17695524.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):113-22 [18162778.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):79-88 [18097482.001]
  • [CommentIn] Blood. 2009 Jul 9;114(2):485-6; author reply 486-7 [19589933.001]
  • (PMID = 18612102.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00040690
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861381
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  • [Other-IDs] NLM/ PMC2532802
  • [Investigator] Mead GM; Jack A; Barrans S; Qian W; Stenning S; Clawson S; Goldstein C; Yule C; Stone J; Glynne-Jones R; Prescott R; Scarffe H
  •  go-up   go-down


Advertisement
4. Martos-Díaz P, Bances-del-Castillo R, Vidal-Laso R, Mancha-de-la-Plata M, Cho-Lee GY, Naval-Gías L: Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma. Med Oral Patol Oral Cir Bucal; 2009 Aug;14(8):e408-10
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma.
  • Among these pathologies, we have focused on intrabone growing tumours such as Burkitt's Lymphoma.
  • Burkitt's Lymphoma is a malignant tumour of B-Cell lymphocyte origin, classified as a Non-Hodgkin's Lymphoma.
  • Three clinical subtypes are described: endemic, sporadic and HIV associated.
  • A high incidence of Burkitt's Lymphoma has been reported in African children.
  • It is known to have a good response to radiotherapy and chemotherapy treatment.
  • This report describes the case of a 29 year-old Spanish man diagnosed with Burkitt's Lymphoma, in which his first and only symptom was bilateral anaesthesia of the lower lip.
  • We have also described the clinical evolution, steps for diagnosis and treatment.
  • [MeSH-major] Burkitt Lymphoma / complications. Cranial Nerve Diseases / etiology. Mandibular Neoplasms / complications. Mandibular Nerve

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415057.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Cerimele F, Battle T, Lynch R, Frank DA, Murad E, Cohen C, Macaron N, Sixbey J, Smith K, Watnick RS, Eliopoulos A, Shehata B, Arbiser JL: Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A; 2005 Jan 4;102(1):175-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.
  • Burkitt's lymphoma (BL) is an aggressive B cell neoplasm, which is one of the most common neoplasms of childhood.
  • It is highly widespread in East Africa, where it appears in endemic form associated with Epstein-Barr virus (EBV) infection, and around the world in a sporadic form in which EBV infection is much less common.
  • In addition to being the first human neoplasm to be associated with EBV, BL is associated with a characteristic translocation, in which the Ig promoter is translocated to constitutively activate the c-myc oncogene.
  • Although many BLs respond well to chemotherapy, a significant fraction fails to respond to therapy, leading to death.
  • Our findings imply that inhibition of ROS may be useful in the treatment of EBV-induced neoplasia.

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6 [9023347.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2899-916 [9205097.001]
  • [Cites] Am J Pathol. 1998 Apr;152(4):865-9 [9546345.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10106-11 [9707608.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3942-5 [9731506.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):709-13 [10826477.001]
  • [Cites] Clin Chim Acta. 2000 Oct;300(1-2):159-69 [10958872.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1937-45 [11106566.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6742-50 [11118209.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):79-82 [11147680.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2171-7 [11360201.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):23077-83 [11304537.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42728-36 [11559697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):715-20 [11805326.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] Mol Med. 2002 Jan;8(1):1-8 [11984000.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):1092-101 [12097418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1265-71 [12168936.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2612-9 [12171892.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):669-75 [12194996.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1207-13 [12368194.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39456-62 [12177067.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3728-33 [12473582.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9790-5 [12514183.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1101-7 [12937151.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1371-8 [14507645.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40778-87 [12909638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15595-600 [14673102.001]
  • [Cites] Semin Cancer Biol. 2004 Apr;14(2):81-91 [15018892.001]
  • [Cites] Circ Res. 2004 May 14;94(9):1219-26 [15059930.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):47-56 [946170.001]
  • [Cites] Cell. 1979 Feb;16(2):313-22 [222455.001]
  • [Cites] Blood. 1986 Mar;67(3):612-5 [3004617.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):25-9 [3025109.001]
  • [Cites] J Exp Pathol. 1987 Summer;3(4):449-56 [2842477.001]
  • [Cites] J Virol. 1992 Nov;66(11):6288-93 [1404592.001]
  • [Cites] J Virol. 1993 Mar;67(3):1292-9 [8382295.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Virol. 1995 Feb;69(2):675-83 [7815530.001]
  • [Cites] J Infect Dis. 1996 Mar;173(3):529-35 [8627013.001]
  • (PMID = 15611471.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR042687; United States / NIAMS NIH HHS / AR / R01 AR047901; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R01 AR 47901
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBNA-2 protein, Human herpesvirus 4; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 0 / Viral Proteins; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC544042
  •  go-up   go-down


6. Malani AK, Gupta C, Weigand RT, Gupta V, Rangineni G: Spinal Burkitt's lymphoma in adults. Clin Lymphoma Myeloma; 2006 Jan;6(4):333-6
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal Burkitt's lymphoma in adults.
  • Adult Burkitt's lymphoma is an uncommon disease.
  • Few cases of spinal involvement in adults with sporadic Burkitt's lymphoma are reported in the literature.
  • Histologic examination revealed a primary Burkitt's lymphoma of the spinal cord.
  • He was treated with aggressive chemotherapy and is now experiencing remission of his disease.
  • We also present a review of the literature for the etiology and clinical features of other spinal lymphomas and Burkitt's lymphoma involving the spine in adults.
  • [MeSH-major] Burkitt Lymphoma / pathology. Epidural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507212.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Huang YH, Wu QL, Zong YS, Feng YF, Liang JZ, Hou JH, Shao Q, Fu J: Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district. Ai Zheng; 2009 Aug;28(8):805-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and Epstein-Barr virus infection status of Burkitt's lymphoma in Guangzhou district.
  • BACKGROUND AND OBJECTIVE: Sporadic Burkitt's lymphoma (sBL) is uncommon and its relation to Epstein-Barr virus (EBV) is unknown in China.
  • This study was to investigate the clinical presentation, morphologic features, immunophenotype and EBV infection status of sBL in Guangzhou district, a prevalent area of EBV infection.
  • RESULTS: From January 2000 to October 2007, 21 cases(0.87%) of sBL were confirmed among 2416 cases of non-Hodgkin's lymphoma(NHL) in Sun Yat-sen University Cancer Center.
  • The 2-year survival rate of 15 patients who received chemotherapy or resection plus chemotherapy was 56.00%.
  • Most patients had lymph node(s) involvement, showing similar morphology and immunophenotype as that of endemic BL.
  • Type I EBV latent infection is associated with 28.57% of cases.
  • [MeSH-major] Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664325.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Epstein-Barr virus encoded RNA 1; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Viral; 0 / interferon regulatory factor-4; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


8. Lin H, Sun XF, Zhen ZJ, Xia Y, Xiang XJ, Ling JY, Liu DG, Xia ZJ, Huang HQ, Luo WB, Zheng L, Lin TY, Guan ZZ: [Clinical analysis of 69 cases of Burkitt's lymphoma]. Ai Zheng; 2008 Apr;27(4):425-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 69 cases of Burkitt's lymphoma].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is a kind of highly aggressive B-cell lymphoma.
  • Its clinical characteristics are different between the endemic areas in Africa and the sporadic areas in America and Europe.
  • There is no large-scale report concerning Burkitt's lymphoma in China yet.
  • This study was to summarize the characteristics of Burkitt's lymphoma in China.
  • METHODS: Clinical data of 69 Burkitt's lymphoma patients, treated from May 1985 to May 2007 in Cancer Center of Sun Yat-sen University, were analyzed.
  • RESULTS: Of the 69 patients, 44 were men and 25 were women, with a median age of 7 (range, 2-72); 5 were at stage I, 9 at stage II, 21 at stage III, and 34 at stage IV, advanced stage (stages III and IV) accounted for 55 (79.7%) patients.
  • Short-term and high intensive chemotherapy with central nervous system prophylaxis could improve the prognosis.
  • CONCLUSION: The clinical characteristics of these 69 Burkitt's lymphoma patients are much similar to those from sporadic areas, but the median age is lower, and the most common involved sites are cervical lymph nodes, abdomen and faciomaxillary-oropharynx.
  • [MeSH-major] Burkitt Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423131.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


9. Otmani N, Khattab M: Oral Burkitt's lymphoma in children: the Moroccan experience. Int J Oral Maxillofac Surg; 2008 Jan;37(1):36-40
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral Burkitt's lymphoma in children: the Moroccan experience.
  • Thirty-seven children with Burkitt's lymphoma of the oral region diagnosed between 1998 and 2005 were reviewed.
  • The mean age at diagnosis was 6.64 years (range 2-15 years) with a mean delay to diagnosis of 41 days (range 10 days-2 months).
  • After chemotherapy, complete remission was seen in 59% of cases.
  • In conclusion, in this series, oral presentation of Burkitt's lymphoma was a component of more widely disseminated disease.
  • The pattern seemed to fall between that of the endemic and the sporadic types.
  • Even with intensive chemotherapy, patients with advanced disease maintained a poor prognosis.
  • [MeSH-major] Burkitt Lymphoma. Mouth Neoplasms

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822883.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


10. Manolopoulos L, Nikolopoulos TP, Yiotakis J, Karapatsas J, Maris A, Ferekidis E: Burkitt's lymphoma in the base of the tongue: differential diagnosis and management. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):226-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in the base of the tongue: differential diagnosis and management.
  • Burkitt's lymphoma is the most common malignancy in African children but can occur sporadically in every country.
  • However, complex chemotherapy regimens can now cure approximately 50-80% of adult patients with Burkitt's lymphoma or small noncleaved lymphoma, and in pediatric populations the cure rate is even higher.
  • Although the African type has a preference to the head and neck region (whereas the sporadic type to the abdomen), involvement of the base of the tongue is extremely rare as only 1 case has ever been reported in the English literature.
  • The present study describes a patient with Burkitt's lymphoma presenting as a single mass in the base of the tongue without any abdominal or other extra-abdominal involvement.
  • The patient was submitted to chemotherapy (intravenous and intrathecal) and skull radiotherapy.
  • Physicians should be aware of the extranodal manifestations of Burkitt's lymphoma and their differential diagnosis in order to achieve early diagnosis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. Tongue Neoplasms / diagnosis. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564099.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


11. Pizza M, Bruniera P, Luporini SM, Marcelino da Silva HR, Borsato ML, de Castro HC, Soares FA, Paes RA: Detection of Epstein-Barr virus in children and adolescents with Burkitt's lymphoma by in situ hybridization using tissue microarrays. Hematology; 2008 Apr;13(2):114-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Epstein-Barr virus in children and adolescents with Burkitt's lymphoma by in situ hybridization using tissue microarrays.
  • In this retrospective study, we evaluated 53 patients diagnosed with Burkitt's lymphoma (BL).
  • Patients were admitted to the Pediatric Department of Santa Casa de São Paulo, Brazil from August 1988 to September 2006.
  • At the time of the diagnosis, the mean age was 6 years.
  • The patients were treated with chemotherapy using two different treatment methods, 30 cases until September 1994 with BGLTI -87 and the other 23 until September of 2006 with BGLTI -96.
  • According to Murphy's classification, 90.2% of the patients were diagnosed as stages III and VI showing an advanced disease at time of diagnosis.
  • Using Tissue Microarrays (TMA); we searched for the expression of the Epstein-Barr virus (EBV) RNA in 50 patients.
  • The frequency of the EBV association with this neoplasia in Brazil is intermediate between the endemic and sporadic forms of disease.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / isolation & purification. In Situ Hybridization
  • [MeSH-minor] Adolescent. Age Factors. Brazil / epidemiology. Child. Child, Preschool. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / diagnosis. Female. Humans. Male. RNA, Viral / analysis. Retrospective Studies. Sex Factors. Survival Analysis. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616879.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


12. Renouf B, Hollville E, Pujals A, Tétaud C, Garibal J, Wiels J: Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia; 2009 Sep;23(9):1557-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
  • p53 inactivation is often observed in Burkitt's lymphoma (BL) cells, because of either mutations in p53 gene or an overexpression of the p53-negative regulator MDM2.
  • Epstein-Barr virus (EBV) is present in virtually 100% of BL cases occurring in endemic areas, but in only 10-20% of sporadic cases.
  • We show here that nutlin-3, a potent antagonist of MDM2, activates the p53 pathway in all BL cell lines harboring wild-type p53, regardless of EBV status.
  • Prior treatment with sublethal doses of nutlin-3 sensitizes EBV(-) or latency I EBV(+) cells to apoptosis induced by etoposide or melphalan, but protects latency III EBV(+) cells. p21(WAF1) which is overexpressed in the latter, is involved in this protective effect, as siRNA-mediated inhibition of p21(WAF1) restores sensitivity to etoposide.
  • Most BL patients with wild-type p53 tumors could therefore benefit from treatment with nutlin-3, after a careful determination of the latency pattern of EBV in infected patients.
  • [MeSH-major] Apoptosis / drug effects. Burkitt Lymphoma / drug therapy. Herpesvirus 4, Human / isolation & purification. Imidazoles / pharmacology. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / physiology. Drug Resistance, Neoplasm. Etoposide / pharmacology. Humans. Poly(ADP-ribose) Polymerases / metabolism

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421231.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Imidazoles; 0 / Piperazines; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


13. Re M, Di Massimo U, Romeo R, Mallardi V: Burkitt-like lymphoma of the sphenoid sinus: case report. Acta Otorhinolaryngol Ital; 2004 Feb;24(1):30-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-like lymphoma of the sphenoid sinus: case report.
  • Burkitt's lymphoma is a malignant endemic neoplasia with a mandibular localization, described for the first time in 1958, in African children.
  • The World Health Organization classification recognises several variants of Burkitt's lymphoma; all are highly malignant B cell lymphomas.
  • Besides Burkitt's sporadic, endemic lymphoma and Burkitt's lymphoma associated with AIDS, the World Health Organization classification includes an "atypical or pleomorphic" variant of Burkitt's lymphoma.
  • This subtype includes those cases diagnosed as "Burkitt-like" lymphoma in the REAL (Revised European-American Classification of Lymphoid Neoplasm).
  • The therapeutic protocol is similar to that used for classic Burkitt's lymphoma, with chemotherapy being standard treatment.
  • Prognosis is extremely poor, with a mean survival of < 1 year.
  • The case is described of a sinus-nasal "Burkitt-like lymphoma", originating within sphenoid sinus.
  • The extremely rare localisation of this histological variant of Burkitt's lymphoma is stressed as well as the extremely aggressive nature of the neoplasm.
  • [MeSH-major] Burkitt Lymphoma / classification. Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus / radiography
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15270431.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Keller C, Savage DG, Rusta-Villa M, Bhagat G, Alobeid B: Primary Burkitt lymphoma of the uterine corpus. Leuk Lymphoma; 2006 Jan;47(1):141-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma of the uterine corpus.
  • This study reports the first well-documented case of sporadic Burkitt lymphoma arising in and confined to the uterine corpus in a 40-year-old woman who presented with vaginal bleeding.
  • Endometrial curettings showed a diffuse infiltrate of medium sized lymphocytes with the characteristic morphologic and immunophenotypic features of Burkitt lymphoma.
  • There was no evidence of extra-uterine disease and the patient is alive without disease 10 months after hysterectomy and chemotherapy.
  • This report demonstrates that Burkitt lymphoma can present as isolated, organ confined disease at unusual sites and with protean symptoms.
  • [MeSH-major] Burkitt Lymphoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Hysterectomy. In Situ Hybridization, Fluorescence / methods. Sensitivity and Specificity. Translocation, Genetic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321839.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Chennupati SK, Govindaraj S, Setzen G, Chiu AG: Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature. Ear Nose Throat J; 2009 Jul;88(7):E07

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult Burkitt lymphoma originating in the sphenoid sinus: case report and review of the literature.
  • Burkitt lymphoma is a high-grade B-cell non-Hodgkin lymphoma.
  • The endemic form of this malignancy occurs primarily in children aged 5 to 7 years, and it presents with jaw and facial bone involvement.
  • The sporadic form affects older children (mean age: 12.2 yr) and often manifests as an abdominal mass; it rarely involves the head and neck.
  • The presence of any type of lymphoma in the paranasal sinuses is rare.
  • We report a case of Burkitt lymphoma that originated in the sphenoid sinus in a 66-year-old white woman.
  • An endoscopic sphenoidotomy was performed to obtain a tissue specimen, and a diagnosis of sporadic Burkitt lymphoma was established on the basis of its clinical, morphologic, and immunohistochemical characteristics.
  • The patient underwent chemotherapy and radiation.
  • This case is one of the few reported cases of true adult Burkitt lymphoma originating in the sphenoid sinus.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sphenoid Sinus
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623516.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


16. Koffi GK, Tolo A, Nanho DC, N'dathz E, Kouassi MY, N'Diaye FD, Kouakou B, Meité N, Ayemou R, Sekongo M, Kouehion P, Meité M, Tea ND, Sangaré A, Sanogo I: Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire. Int J Hematol; 2010 Jun;91(5):838-43
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
  • African Burkitt lymphomas (BL) are highly aggressive lymphomas mainly affecting children and young adults in Africa.
  • This lymphoma was marked by its high sensitivity to chemotherapy in comparison to Sporadic Burkitt lymphoma.
  • In this study, we evaluated the treatment response and survival of patients with CMA protocol.
  • Eighty-five of the 105 children registered were evaluated for response; there were 46 boys and 39 girls, whose age at diagnosis ranged from 3 to 18 years (median 11 years), admitted to the Hematology National Teaching Hospital of Abidjan in the period 1998-2008 with a diagnosis of BL on histological review and who were given CMA chemotherapy with curative intent are included in this analysis.
  • CMA protocol is a low intermediate regimen of 3 drugs [Cytarabin (ara-C), Methotrexate (MTX), and Cyclophosphamide] with CNS-directed treatment by intrathecal MTX, ara-C and corticosteroid.
  • Fifty-five of 85 patients obtained CR after induction therapy and 10 after 3 supplementary cycle because of partial response.
  • Fifty-three of patients were alive in first CR at a median survival rate period of 2 years (range 82 days to 9 years) and are continuously disease free from Burkitt lymphomas.
  • Twelve patients relapse after CR and died of lymphoma progression.
  • More than 32 patients died, as a result of lymphoma progression.
  • In conclusion, CMA protocol shows the high sensitivity of African Burkitt lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cote d'Ivoire. Female. Humans. Male. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] Tunis Med. 1984 Jan-Feb;62(1):73-7 [6528380.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):741-6 [6683647.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • (PMID = 20480270.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Chuang SS, Huang WT, Hsieh PP, Jung YC, Ye H, Du MQ, Lu CL, Cho CY, Hsiao SC, Hsu YH, Lin KJ: Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology; 2008 Mar;52(4):427-35
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features.
  • AIMS: To characterize the clinicopathological features of sporadic Burkitt lymphoma (BL).
  • Twenty-eight patients received chemotherapy including 13/16 (81%) paediatric and 3/12 (25%) adult patients with appropriate regimens; 16 (57%) received CNS prophylaxis.
  • CONCLUSIONS: Sporadic paediatric and adult BLs were phenotypically and genotypically similar.
  • The poor outcome in adult patients might be related to incorrect diagnosis and inappropriate treatment.
  • [MeSH-major] Burkitt Lymphoma / pathology. Central Nervous System Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315595.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


18. Thielen C, Herens C, Fassotte MF, Detrooz E, Drion P, Diss T, Boniver J, de Leval L: Establishment and characterisation of two novel human KSHV- and EBV-negative Burkitt cell lines, GAL-01 and GAL-02, from a primary lymphomatous effusion. Eur J Haematol; 2006 Oct;77(4):318-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterisation of two novel human KSHV- and EBV-negative Burkitt cell lines, GAL-01 and GAL-02, from a primary lymphomatous effusion.
  • OBJECTIVES: Burkitt's lymphoma (BL) is a highly aggressive mature B-cell neoplasm comprising endemic, sporadic and immunodeficiency-associated variants.
  • In this study, we succeeded in establishing two human cell lines, GAL-01 and GAL-02, from a HIV-negative patient with Epstein-Barr virus (EBV) -negative sporadic BL presenting as an effusion.
  • The in vivo effusion occurred in a very peculiar clinical setting; the patient having a previous history of intestinal diffuse large B-cell lymphoma.
  • METHODS: The morphologic, immunophenotypic and molecular genetic features of GAL cell lines are reported and compared with those of the parental tumour.
  • The findings clearly demonstrated that the Burkitt effusion did not represent disease progression of the intestinal tumour, but represented a second primary haematological malignancy.
  • CONCLUSIONS: GAL-01 and GAL-02, two novel EBV-negative human BL cell lines represent a potentially useful experimental model to study the biology of BL possibly including the resistance to chemotherapy.
  • [MeSH-major] Lymphoma / pathology


19. Sharma A, Raina V, Gujral S, Kumar R, Tandon R, Jain P: Burkitt's lymphoma of stomach: A case report and review of literature. Am J Hematol; 2001 May;67(1):48-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of stomach: A case report and review of literature.
  • Primary gastrointestinal non-Hodgkin's lymphoma is a distinct clinicopathological entity.
  • Non-endemic Burkitt's lymphoma (high-grade, small non-cleaved lymphocytic type) is rare in non-HIV adult population.
  • We hereby report Burkitt's lymphoma of stomach in a non-HIV adult.
  • Patient was treated using a third generation chemotherapy protocol without any surgical resection.
  • The patient relapsed within 3 months of completion of primary treatment and died of progressive disease.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11279657.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement